{
    "2020-09-08": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Novartis (NVS) Releases Positive Data on Enerzair Breezhaler",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Positive Data",
                        "Enerzair Breezhaler"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Understanding Novartis's Unusual Options Activity",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Options Activity",
                        "Unusual"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-15",
                "original_text": "Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum",
                "features": {
                    "keywords": [
                        "Novartis",
                        "ACTRIMS-ECTRIMS",
                        "MS Portfolio",
                        "Life-changing Therapies"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}